

Anat Stemmer-Rachamimov

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9022679/publications.pdf>

Version: 2024-02-01

51
papers

4,872
citations

361413

20
h-index

254184

43
g-index

54
all docs

54
docs citations

54
times ranked

10349
citing authors

#	ARTICLE	IF	CITATIONS
1	Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. <i>Cell</i> , 2018, 175, 998-1013.e20.	28.9	1,260
2	Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. <i>Cancer Discovery</i> , 2015, 5, 1164-1177.	9.4	821
3	Resistance to checkpoint blockade therapy through inactivation of antigen presentation. <i>Nature Communications</i> , 2017, 8, 1136.	12.8	686
4	Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. <i>Genetics in Medicine</i> , 2021, 23, 1506-1513.	2.4	290
5	Histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumor in patients with neurofibromatosis 1—a consensus overview. <i>Human Pathology</i> , 2017, 67, 1-10.	2.0	275
6	Directly visualized glioblastoma-derived extracellular vesicles transfer RNA to microglia/macrophages in the brain. <i>Neuro-Oncology</i> , 2016, 18, 58-69.	1.2	245
7	Single-cell transcriptomic atlas of the human retina identifies cell types associated with age-related macular degeneration. <i>Nature Communications</i> , 2019, 10, 4902.	12.8	203
8	Clinical Features of Schwannomatosis: A Retrospective Analysis of 87 Patients. <i>Oncologist</i> , 2012, 17, 1317-1322.	3.7	171
9	Genomic landscape of high-grade meningiomas. <i>Npj Genomic Medicine</i> , 2017, 2, .	3.8	130
10	An update on the CNS manifestations of neurofibromatosis type 2. <i>Acta Neuropathologica</i> , 2020, 139, 643-665.	7.7	102
11	Rapid Intraoperative Molecular Characterization of Glioma. <i>JAMA Oncology</i> , 2015, 1, 662.	7.1	68
12	Sacrococcygeal chordomas in patients with tuberous sclerosis complex show somatic loss of <i>TSC1</i> or <i>TSC2</i> . <i>Genes Chromosomes and Cancer</i> , 2004, 41, 80-85.	2.8	60
13	Expression of SMARCB1 (INI1) mutations in familial schwannomatosis. <i>Human Molecular Genetics</i> , 2012, 21, 5239-5245.	2.9	51
14	Absence of Alzheimer Disease Neuropathologic Changes in Eyes of Subjects With Alzheimer Disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 2017, 76, 376-383.	1.7	50
15	A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas. <i>Oncotarget</i> , 2015, 6, 16981-16997.	1.8	46
16	YAP Mediates Tumorigenesis in Neurofibromatosis Type 2 by Promoting Cell Survival and Proliferation through a COX-2/EGFR Signaling Axis. <i>Cancer Research</i> , 2016, 76, 3507-3519.	0.9	44
17	Analysis of intratumor heterogeneity in Neurofibromatosis type 1 plexiform neurofibromas and neurofibromas with atypical features: Correlating histological and genomic findings. <i>Human Mutation</i> , 2018, 39, 1112-1125.	2.5	34
18	NLRP3 inflammasome activation in human vestibular schwannoma: Implications for tumor-induced hearing loss. <i>Hearing Research</i> , 2019, 381, 107770.	2.0	33

#	ARTICLE	IF	CITATIONS
19	Targeting the cMET pathway augments radiation response without adverse effect on hearing in NF2 schwannoma models. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E2077-E2084.	7.1	32
20	Characterization and oncolytic virus targeting of FAP-expressing tumor-associated pericytes in glioblastoma. Acta Neuropathologica Communications, 2020, 8, 221.	5.2	26
21	Epigenomic, genomic, and transcriptomic landscape of schwannomatosis. Acta Neuropathologica, 2021, 141, 101-116.	7.7	26
22	A new patient-derived orthotopic malignant meningioma model treated with oncolytic herpes simplex virus. Neuro-Oncology, 2016, 18, 1278-1287.	1.2	25
23	EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma. Neuro-Oncology, 2018, 20, 1185-1196.	1.2	22
24	Losartan prevents tumor-induced hearing loss and augments radiation efficacy in NF2 schwannoma rodent models. Science Translational Medicine, 2021, 13, .	12.4	21
25	Gene therapy with apoptosis-associated speck-like protein, a newly described schwannoma tumor suppressor, inhibits schwannoma growth in vivo. Neuro-Oncology, 2019, 21, 854-866.	1.2	18
26	Long-Term Therapeutic Efficacy of Intravenous AAV-Mediated Hamartin Replacement in Mouse Model of Tuberous Sclerosis Type 1. Molecular Therapy - Methods and Clinical Development, 2019, 15, 18-26.	4.1	17
27	Gene therapy for tuberous sclerosis complex type 2 in a mouse model by delivery of AAV9 encoding a condensed form of tuberin. Science Advances, 2021, 7, .	10.3	17
28	The AAV9 Variant Capsid AAV-F Mediates Widespread Transgene Expression in Nonhuman Primate Spinal Cord After Intrathecal Administration. Human Gene Therapy, 2022, 33, 61-75.	2.7	16
29	Stochastic Model of Tsc1 Lesions in Mouse Brain. PLoS ONE, 2013, 8, e64224.	2.5	16
30	Survival benefit and phenotypic improvement by hamartin gene therapy in a tuberous sclerosis mouse brain model. Neurobiology of Disease, 2015, 82, 22-31.	4.4	14
31	Anti-VEGF treatment improves neurological function in tumors of the nervous system. Experimental Neurology, 2018, 299, 326-333.	4.1	14
32	Mosaicism for Receptor Tyrosine Kinase Activation in a Glioblastoma Involving Both PDGFRA Amplification and NTRK2 Fusion. Oncologist, 2021, 26, 919-924.	3.7	6
33	A proteasome-resistant fragment of NIK mediates oncogenic NF- κ B signaling in schwannomas. Human Molecular Genetics, 2019, 28, 572-583.	2.9	5
34	Remote acute demyelination after focal proton radiation therapy for optic nerve meningioma. Journal of Clinical Neuroscience, 2015, 22, 1367-1369.	1.5	4
35	Multi-center, single arm phase II study of the dual mTORC1/mTORC2 inhibitor vistusertib for patients with recurrent or progressive grade II-III meningiomas.. Journal of Clinical Oncology, 2021, 39, 2024-2024.	1.6	4
36	Assessing interobserver variability and accuracy in the histological diagnosis and classification of cutaneous neurofibromas. Neuro-Oncology Advances, 2020, 2, i117-i123.	0.7	3

#	ARTICLE	IF	CITATIONS
37	A case of antisynthetase syndrome with thrombotic thrombocytopenic purpura. <i>Rheumatology</i> , 2021, 60, e143-e145.	1.9	2
38	Status and Recommendations for Incorporating Biomarkers for Cutaneous Neurofibromas Into Clinical Research. <i>Neurology</i> , 2021, 97, S42-S49.	1.1	2
39	ACTR-36. A SINGLE ARM PHASE 2 STUDY OF THE DUAL mTORC1/mTORC2 INHIBITOR VISTUSERTIB PROVIDED ON AN INTERMITTENT SCHEDULE FOR NEUROFIBROMATOSIS 2 PATIENTS WITH PROGRESSIVE OR SYMPTOMATIC MENINGIOMAS. <i>Neuro-Oncology</i> , 2018, 20, vi19-vi19.	1.2	1
40	Vestibular Traumatic Neuroma Following Temporal Bone Fracture. <i>Otology and Neurotology</i> , 2019, 40, e62-e65.	1.3	1
41	Effect of antiangiogenic therapy on tumor-associated macrophages in recurrent glioblastoma.. <i>Journal of Clinical Oncology</i> , 2012, 30, 2010-2010.	1.6	1
42	Neurofibromatoses. <i>Journal of Neuropathology and Experimental Neurology</i> , 2009, 68, 111-111.	1.7	0
43	Sporadic NF2 Mosaic: Multiple spinal schwannomas presenting with severe, intractable pain following pregnancy. <i>Interdisciplinary Neurosurgery: Advanced Techniques and Case Management</i> , 2017, 10, 142-145.	0.3	0
44	PATH-08. THE IVY GLIOBLASTOMA PATIENT ATLAS - A NOVEL CLINICAL AND RADIO-GENOMICS RESOURCE FOR EARLY PHASE CLINICAL TRIAL DESIGN AND INTERPRETATION. <i>Neuro-Oncology</i> , 2018, 20, vi159-vi159.	1.2	0
45	GENE-08. SCHWANNOMATOSIS SCHWANNOMAS HARBOR DISTINCT DNA METHYLATION PROFILES. <i>Neuro-Oncology</i> , 2018, 20, vi104-vi104.	1.2	0
46	TMOD-23. PRECLINICAL DRUG EVALUATION IN A GENETICALLY ENGINEERED MINIPIG MODEL OF NEUROFIBROMATOSIS TYPE 1. <i>Neuro-Oncology</i> , 2019, 21, vi267-vi267.	1.2	0
47	Prognostic value of tumor microinvasion and metalloproteinases expression in intracranial pediatric ependymomas. <i>FASEB Journal</i> , 2008, 22, 706.8.	0.5	0
48	Kinome Screen Reveals SGK1 as a Therapeutic Target for NF2: Inhibition of mTORC1/2 is More Effective than Rapamycin. <i>FASEB Journal</i> , 2015, 29, 889.4.	0.5	0
49	EPCO-04. GENOMIC AND EPIGENOMIC HALLMARKS OF SCHWANNOMATOSIS SCHWANNOMAS. <i>Neuro-Oncology</i> , 2020, 22, ii69-ii70.	1.2	0
50	CTNI-54. A SINGLE ARM PHASE II STUDY OF THE DUAL MTORC1/MTORC2 INHIBITOR VISTUSERTIB PROVIDED FOR SPORADIC PATIENTS WITH GRADE II-III MENINGIOMAS THAT RECUR OR PROGRESS AFTER SURGERY AND RADIATION. <i>Neuro-Oncology</i> , 2021, 23, vi72-vi72.	1.2	0
51	Abstract 2287: Dissecting the heterogeneity of central nervous system hemangioblastomas by single-cell and single-nuclei RNA sequencing. <i>Cancer Research</i> , 2022, 82, 2287-2287.	0.9	0